Mural Oncology plc EBIT

Mural Oncology plc (MURA) currently reports a EBIT of $-36M as of September 2025. That compares with $-130M in the prior-year period — up 71.7% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Mural Oncology plc's EBIT history and peer comparisons.

Mural Oncology plc's EBIT increased from $-130M to $-36M — a 71.7% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mural Oncology plc's EBIT of $-36M is lower than the Healthcare sector average of $23B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Mural Oncology plc reported $-36M in EBIT as of September 2025. That compares with $-130M in the prior-year period — up 71.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-36M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Mural Oncology plc, and consider following MURA for alerts when major investors trade the stock.